In the procedure these CD34+ cells are stimulated to grow and multiply, before being induced to enter the bloodstream. The cells are then collected, processed and injected into targeted areas of the heart.
Around 450 patients will be enrolled in the trial and split into three treatment groups:
· one group who will receive the therapy,
· third group who will receive standard medical care